ChromaDex(US:CDXC)2025-05-07 20:01Financial Performance - Total net sales reached $30.5 million, an increase of $8.3 million or 38% year-over-year, with a gross margin of 63.4%[1][4] - Net income was $5.1 million, or $0.07 per share, compared to a net loss of $0.5 million or $(0.01) per share in the prior year quarter[7][20] - Adjusted EBITDA improved to $4.9 million, up from $0.7 million in the first quarter of 2024[7][20] - Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% year-over-year[4][5] - Cash provided by operations was $7.9 million, compared to $0.3 million in the prior year[8][20] - Net income for Q1 2025 was reported at $5,063,000, compared to a net income of $7,179,000 in Q4 2024, indicating a decrease of 29.5%[27] - Adjusted EBITDA for Q1 2025 was $4,894,000, up from $3,371,000 in Q4 2024, reflecting a growth of 45.0%[27] Future Outlook - The company expects full year 2025 net sales growth between 20% and 25%, an increase from the previous estimate of approximately 18%[4][9] Expenses and Liabilities - Selling and marketing expenses as a percentage of net sales improved by 380 basis points to 26.6%[4][10] - General and administrative expenses are expected to increase by approximately $7.0 to $8.0 million due to revised share-based compensation estimates[4][9] - Total current liabilities increased to $20,837,000 as of March 31, 2025, from $17,948,000 on December 31, 2024, an increase of 10.5%[23] Assets and Equity - Total assets increased to $81,337,000 as of March 31, 2025, up from $68,278,000 on December 31, 2024, representing a growth of 19.1%[23] - Cash and cash equivalents at the end of Q1 2025 reached $55,616,000, compared to $27,565,000 at the end of Q1 2024, marking a 101.5% increase[25] - Total stockholders' equity increased to $55,345,000 as of March 31, 2025, up from $46,094,000 on December 31, 2024, a growth of 20.0%[23] Cash Flow - Net cash provided by operating activities for Q1 2025 was $7,883,000, a significant increase from $295,000 in Q1 2024[25] - The company reported a net increase in cash and cash equivalents of $10,956,000 for Q1 2025, compared to an increase of $240,000 in Q1 2024[25] Inventory and Receivables - Trade receivables decreased to $7,052,000 as of March 31, 2025, down from $7,768,000 on December 31, 2024, a decline of 9.2%[23] - Inventories rose to $11,185,000 as of March 31, 2025, compared to $9,192,000 on December 31, 2024, an increase of 21.7%[23] Corporate Changes - The company announced a corporate name change to Niagen Bioscience, Inc. and began trading under the new Nasdaq ticker "NAGE" effective March 19, 2025[4] - The company expanded its NAD+ precursor patent portfolio with a newly granted patent covering NR salt forms[4]